Literature DB >> 10348828

Transforming growth factor alpha activates Ha-Ras in human pancreatic cancer cells with Ki-ras mutations.

T Seufferlein1, J Van Lint, S Liptay, G Adler, R M Schmid.   

Abstract

BACKGROUND & AIMS: The aim of this study was to identify signaling pathways that mediate cell proliferation in response to a Ras-activating growth factor, transforming growth factor (TGF)-alpha, in two pancreatic cancer cell lines with constitutively active Ki-Ras, MiaPaCa-2, and Panc-1.
METHODS: ERK1/-2- and p90(rsk) activation were determined by immune complex kinase assays. AP-1 and E74 activation were assessed in transient transfections using luciferase reporter plasmids. Ha-Ras activation was determined using a glutathione S-transferase fusion protein comprising the Ras-binding domain of Raf and by immunocytochemistry, growth by DNA synthesis and colony formation in softagar.
RESULTS: TGF-alpha stimulated activation of ERK1/-2, which was dependent on MEK-1, but independent of PKC activity. TGF-alpha-induced activation of an AP-1 reporter plasmid also required MEK-1 and Ras activity. Using an E74 reporter plasmid, we demonstrate that TGF-alpha indeed activates Ras in both cell lines. In particular, TGF-alpha induced membrane translocation and activation of the Ras isoform Ha-Ras. Finally, TGF-alpha-stimulated DNA synthesis and clonal growth in soft agar were prevented by treatment of cells with a MEK-1 inhibitor or a Ras farnesyl transferase inhibitor.
CONCLUSIONS: The Ha-Ras-ERK cascade plays an important role in TGF-alpha-induced growth of pancreatic cancer cells with activating Ki-ras mutations. Inhibitors of this cascade could constitute novel anticancer agents for pancreatic tumors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348828     DOI: 10.1016/s0016-5085(99)70509-3

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  13 in total

1.  Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer.

Authors:  Nada Milosevic; Benjamin Kühnemuth; Leonie Mühlberg; Stefanie Ripka; Heidi Griesmann; Carolin Lölkes; Malte Buchholz; Daniela Aust; Christian Pilarsky; Sebastian Krug; Thomas Gress; Patrick Michl
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

Review 2.  Novel protein kinases in pancreatic cell growth and cancer.

Authors:  Thomas Seufferlein
Journal:  Int J Gastrointest Cancer       Date:  2002

3.  Ras isoform abundance and signalling in human cancer cell lines.

Authors:  J Omerovic; D E Hammond; M J Clague; I A Prior
Journal:  Oncogene       Date:  2007-11-12       Impact factor: 9.867

4.  Phosphatome profiling reveals PTPN2, PTPRJ and PTEN as potent negative regulators of PKB/Akt activation in Ras-mutated cancer cells.

Authors:  Jasminka Omerovic; Michael J Clague; Ian A Prior
Journal:  Biochem J       Date:  2010-01-27       Impact factor: 3.857

5.  Tissue plasminogen activator in murine exocrine pancreas cancer: selective expression in ductal tumors and contribution to cancer progression.

Authors:  Susana Aguilar; Josep M Corominas; Núria Malats; José A Pereira; Marlène Dufresne; Francisco X Real; Pilar Navarro
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

Review 6.  KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops.

Authors:  Guido Eibl; Enrique Rozengurt
Journal:  Semin Cancer Biol       Date:  2017-10-24       Impact factor: 15.707

Review 7.  Biological approaches to therapy of pancreatic cancer.

Authors:  Han Hsi Wong; Nicholas R Lemoine
Journal:  Pancreatology       Date:  2008-08-25       Impact factor: 3.996

8.  Crosstalk of protein kinase C ε with Smad2/3 promotes tumor cell proliferation in prostate cancer cells by enhancing aerobic glycolysis.

Authors:  Wanfu Xu; Fangyin Zeng; Songyu Li; Guihuan Li; Xiaoju Lai; Qiming Jane Wang; Fan Deng
Journal:  Cell Mol Life Sci       Date:  2018-09-12       Impact factor: 9.261

9.  Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells.

Authors:  Keith A Cengel; K Rahn Voong; Sanjay Chandrasekaran; Laurence Maggiorella; Thomas B Brunner; Eric Stanbridge; Gary D Kao; W Gillies McKenna; Eric J Bernhard
Journal:  Neoplasia       Date:  2007-04       Impact factor: 5.715

Review 10.  Ras proteins: paradigms for compartmentalised and isoform-specific signalling.

Authors:  J Omerovic; A J Laude; I A Prior
Journal:  Cell Mol Life Sci       Date:  2007-10       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.